References
- Food and Drug Administration Information for healthcare professionals: exenatide (marketed as Byetta) – 8/2008 update Available from: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm124713.htm Accessed October 23, 2012
- Food and Drug Administration Information for healthcare professionals – acute pancreatitis and sitagliptin (marketed as Januvia and Janumet) Available from: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm183764.htm Accessed October 23, 2012
- Food and Drug Administration Information for healthcare professionals – Victoza (liraglutide [rDNA origin]) injection: REMS – risk of thyroid C-cell tumors, acute pancreatitis Available from: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm258826.htm Accessed October 23, 2012
- Garg R Chen W Pendergrass M Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis Diabetes Care 2010 33 11 2349 2354 20682680
- Gonzalez-Perez A Schlienger RG Rodríguez LA Acute pancreatitis in association with type 2 diabetes and antidiabetic drugs: a population-based cohort study Diabetes Care 2010 33 12 2580 2585 20833867
- Noel RA Braun DK Patterson RE Bloomgren GL Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: a retrospective cohort study Diabetes Care 2009 32 5 834 838 19208917
- American Gastroenterological Association AGA Institute medical position statement on acute pancreatitis Gastroenterology 2007 132 5 2019 2021 17484893
- Vantyghem MC Haye S Balduyck M Changes in serum amylase, lipase and leukocyte elastase during diabetic ketoacidosis and poorly controlled diabetes Acta Diabetol 1999 36 1–2 39 44 10436251
- Manjuck J Zein J Carpati C Astiz M Clinical significance of increased lipase levels on admission to the ICU Chest 2005 127 1 246 250 15653991
- Gullo L Lucrezio L Migliori M Benign pancreatic hyperenzy-memia or Gullo’s syndrome Adv Med Sci 2008 53 1 1 5 18650145
- World Medical Association Declaration of Helsinki: Ethical principles for medical research involving human subjects 2008 Available from: http://www.wma.net/en/30publications/10policies/b3/index.html Accessed October 23, 2012
- Semakula C Vandewalle CL Van Schravendijk CFH Abnormal circulating pancreatic enzyme activities in more than twenty-five percent of recent-onset insulin-dependent diabetic patients: association of hyperlipasemia with high-titer islet cell antibodies. Belgian Diabetes Registry Pancreas 1996 12 4 321 333 8740397
- Frossard JL Steer ML Pastor CM Acute pancreatitis Lancet 2008 371 9607 143 152 18191686
- Yadav D Lowenfels AB Trends in the epidemiology of the first attack of acute pancreatitis: a systematic review Pancreas 2006 33 4 323 330 17079934
- Martínez J Johnson CD Sánchez-Payá J Obesity is a definitive risk factor of severity and mortality in acute pancreatitis: an updated meta-analysis Pancreatology 2006 6 3 206 209 16549939
- Solanki NS Barreto SG Saccone GT Acute pancreatitis due to diabetes: the role of hyperglycaemia and insulin resistance Pancreatology 2012 12 3 234 239 22687379
- Banks PA Freeman ML Practice guidelines in acute pancreatitis Am J Gastroenterol 2006 101 10 2379 2400 17032204